Dr. Ardigò received his degree in Medicine and the specialization in Internal Medicine at the University of Parma (Italy). After a post-doctoral fellowship at Stanford University (California, US) he obtained a PhD degree in Cardiovascular Pathophysiology at the University of Parma. He is author of more than 40 indexed papers. He joined Chiesi in 2010 where acted as Clinical Lead in the development and registration of the first stem cell therapy in the EU (Holoclar®) and has been leading the cross-company team that led to the treatment of the first patient with a commercial gene therapy in EU (in alliance with uniQure BV). He is chairman of the Therapies Scientific Committee of IRDiRC (International Rare Diseases Research Consortium) and a member of the EBE-EFPIA ATMP Working Group.